A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Chronic Obstructive Pulmonary Disease and a History of Exacerbations

Updated on 25 March 2021


A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Chronic Obstructive Pulmonary Disease and a History of Exacerbations


We will examine whether or not lebrikizumab improves lung function in people with COPD. We also hope to learn whether lebrikizumab reduces the number of COPD exacerbations and improves symptoms in people who do not have good control of their COPD despite being treated with a long-acting bronchodilator and an inhaled corticosteroid. We are also testing whether blood tests to measure the level of a protein called periostin and a type of cell called eosinophils can be used to identify which people are likely to benefit from lebrikizumab

Clinical Study IdentifierTX142878
Last Modified on25 March 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 40 yrs and 80 yrs?
Gender: Male or Female
Able and willing to provide written informed consent and to comply with the study protocol
Age 40 - 80 years old at Visit 1
Able and willing to use the electronic device for patient-reported data collection
Documented history of COPD diagnosis for ≥ 12 months prior to Visit 1
Post-bronchodilator FEV1/FVC< 0.70 at Visit 1 or Visit 2
Post-bronchodilator FEV1 < 80% predicted at Visit 1 or Visit 2
Documented history of one or more acute COPD exacerbations that required treatment with systemic corticosteroids and/or antibiotics or hospitalization within 12 months prior to Visit 1
Current tobacco smoker or former smoker (having stopped smoking for at least 6 months prior to Visit 1) with a history of smoking ≥ 10 pack-years (20 cigarettes/day for 10 years). A former smoker may not have used inhaled tobacco products or inhaled marijuana within the past 3 months (e.g., cigarettes, cigars, electronic cigarettes, or pipe tobacco)
On ICS therapy for ≥ 6 months prior to Visit 1
On an eligible bronchodilator medication (LABA, LAMA, or both) for ≥ 6 months prior to Visit 1
Chest X-ray or CT scan within 6 months prior to Visit 1 or chest X-ray during the screening period (prior to Visit 2) that confirms the absence of clinically significant lung disease besides COPD
Demonstrated adherence with background COPD inhaler medication during the screening period. Adherence is defined as patients responding affirmatively that they have taken their inhaler therapy ≥ 70% of days during the screening period (Visits 1−2), as recorded in their eDiary
For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of < 1% per year for the duration of the study (during the placebo-controlled period and the safety follow-up period)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note